Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

 

Current news and events

Centre for Advanced Cell and Gene therapy launched

From left: Dag Josefsen, Johanna Olweus and Karl-Johan Malmberg
From left: Dag Josefsen, Johanna Olweus and Karl-Johan Malmberg

Cell and gene therapy form two of the most dynamic research areas world-wide and provide fundamentally new therapies for diseases without available treatment. A donor consortium consisting of Svanhild and Arne Must´s Foundation for Medical Research (lead donor), RADFORSK oncology research fund and the Norwegian Cancer Society, has committed 50 MNOK to form a Centre for Advanced Cell and Gene therapy (ACT Centre) located in clean room facilities at the OUH. The launching of the centre was covered by the Norwegian Broadcasting Corporation (NRK) May 2nd.

Annual Report from the Institute for Cancer Research for 2020

The Annual Report from the Institute for Cancer Research for 2020 is now published.
Institute head Kjetil Taskén says: "We have kept the activity up through the pandemic based on the production numbers. You can read about the exciting research by almost 400 people in 25 research groups and 6 core facilities at the ICR. Activities in the CanCell CoE, two KG Jebsen Centres and two OUH strategic research areas and other activities in precision medicine and cell therapy where our researchers are involved are also covered."

Webinar, May 11, 2021:Health Research in Horizon Europe

Successful EU applicants Ira Haraldsen and Ole Andreassen will share their experiences.
Successful EU applicants Ira Haraldsen and Ole Andreassen will share their experiences.

The Research Council of Norway, Oslo University Hospital, and the Faculty of Medicine, UiO invite researchers to a webinar about funding of health and medical research in Horizon Europe.
Time and place: May 11, 2021 1:00 PM–4:00 PM, on Zoom
Deadline for registration: May 7
The event is co-hosted by Research Council Norway, Oslo University Hospital and Faculty of Medicine at UIO, and is primarily targeted towards researchers at OUS and UiO interested in Horizon Europe and funding opportunities therein.

Pål Kristian Selbo receives NOK 3.75 million from Radforsk Investment Foundation

Pål Kristian Selbo
Pål Kristian Selbo

Radforsk Investment Foundation has granted five research projects a total amount of MNOK 4.95 to further develop exciting research projects within photodynamic treatment and photochemical internalization.
This year, one of the projects has been awarded a total of NOK 3.75 million over three years. It is a project led by researcher Pål Selbo from the Department of Radiation Biology at Institute for Cancer Research entitled «Novel Photobiological Strategies Counteracting Tumor Immune Escape».
Selbo has been interviewed (in Norwegian) for the Radium podcast on basis of the Radforsk support.

PANCAIM: A European consortium to improve pancreatic cancer treatment with artificial intelligence optimizing, integrating genomics and medical imaging

PANCAIM will optimize and integrate genomics and imaging phenomics using artificial intelligence (AI). The aim is to help clinical decision-makers to give the right treatment to the right patients at the right time. The PANCAIM project was granted >8 M€ where >1 M€ was granted OUS.

The PANCAIMs OUS team: Tero Aittokallio, Elin Kure, Gry A. Geitvik, Caroline Verbeke and Knut Jørgen Labori.

Units and subpages

View all subunitsHide all subunits